119 related articles for article (PubMed ID: 38018304)
1. Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Yoshimaru Y; Nagaoka K; Tanaka K; Narahara S; Inada H; Kurano S; Tokunaga T; Iio E; Watanabe T; Setoyama H; Tateyama M; Yoshida K; Tsunoda T; Nakamura Y; Tanaka M; Sasaki Y; Tanaka Y
Hepatol Res; 2024 May; 54(5):451-464. PubMed ID: 38018304
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Suzuki N; Hazama S; Iguchi H; Uesugi K; Tanaka H; Hirakawa K; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Shimizu R; Hayashi H; Sakata K; Takenouchi H; Matsui H; Shindo Y; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Nakamura Y; Oka M; Nagano H
Cancer Sci; 2017 Jan; 108(1):73-80. PubMed ID: 27783849
[TBL] [Abstract][Full Text] [Related]
4. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Miyazawa M; Katsuda M; Maguchi H; Katanuma A; Ishii H; Ozaka M; Yamao K; Imaoka H; Kawai M; Hirono S; Okada KI; Yamaue H
Int J Cancer; 2017 Feb; 140(4):973-982. PubMed ID: 27861852
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
[TBL] [Abstract][Full Text] [Related]
7. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients.
Okuyama R; Aruga A; Hatori T; Takeda K; Yamamoto M
Oncoimmunology; 2013 Nov; 2(11):e27010. PubMed ID: 24498547
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma.
Zhang JX; Chen P; Liu S; Zu QQ; Shi HB; Zhou CG
J Hepatocell Carcinoma; 2022; 9():265-272. PubMed ID: 35388358
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.
Tamura R; Yamanobe Y; Fujioka M; Morimoto Y; Fukumura M; Nakaya M; Oishi Y; Sato M; Ueda R; Fujiwara H; Hikichi T; Noji S; Oishi N; Ozawa H; Ogawa K; Kawakami Y; Ohira T; Yoshida K; Toda M
J Clin Oncol; 2024 May; ():JCO2302376. PubMed ID: 38776485
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma.
Gu H; Li J; You N; Wu K; Wang Z; Wang L; Zhu Y; Liu Q; Peng X; Zheng L
Ann Transl Med; 2020 Dec; 8(24):1677. PubMed ID: 33490189
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
14. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Hsu C; Yang TS; Huo TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL
J Hepatol; 2012 May; 56(5):1097-1103. PubMed ID: 22245891
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.
Han CL; Yan YC; Yan LJ; Meng GX; Yang CC; Liu H; Ding ZN; Dong ZR; Hong JG; Chen ZQ; Li T
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1425-1441. PubMed ID: 35482077
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Deng L; Sun Y; Wang H; Liao C; Li D; Xu G; Yang X
J Hepatocell Carcinoma; 2024; 11():29-38. PubMed ID: 38223554
[TBL] [Abstract][Full Text] [Related]
18. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
